Quénet, F., Elias, D., Roca, L., Goéré, D., Ghouti, L., Pocard, M., . . . RAT, P. (2021). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. The lancet oncology, 22(2), 256-266. https://doi.org/10.1016/S1470-2045(20)30599-4
Chicago-Zitierstil (17. Ausg.)Quénet, François, et al. "Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Versus Cytoreductive Surgery Alone for Colorectal Peritoneal Metastases (PRODIGE 7): A Multicentre, Randomised, Open-label, Phase 3 Trial." The Lancet Oncology 22, no. 2 (2021): 256-266. https://doi.org/10.1016/S1470-2045(20)30599-4.
MLA-Zitierstil (9. Ausg.)Quénet, François, et al. "Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Versus Cytoreductive Surgery Alone for Colorectal Peritoneal Metastases (PRODIGE 7): A Multicentre, Randomised, Open-label, Phase 3 Trial." The Lancet Oncology, vol. 22, no. 2, 2021, pp. 256-266, https://doi.org/10.1016/S1470-2045(20)30599-4.